Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Antiviral Res. 2015 Jun 12;121:16–23. doi: 10.1016/j.antiviral.2015.06.005

Figure 3. Antiviral efficacy and cytotoxicity of 30N12, 16F19, and 4F17 against HSV-1.

Figure 3

(a) Efficacy of varying drugs concentrations against HSV-1 lytic infection; FC performed 24hpi. (b) Neurotoxicity of 30N12, 16F19, and 4F17 without HSV-1 infection was assessed by FC using fixable viability dye. The data represent an average of three independent experiments. Error bars represent standard deviations.